PMID- 11142480
OWN - NLM
STAT- MEDLINE
DCOM- 20010322
LR  - 20200203
IS  - 0923-7534 (Print)
IS  - 0923-7534 (Linking)
VI  - 11
IP  - 11
DP  - 2000 Nov
TI  - Biological markers may add to prediction of outcome achieved by the International 
      Prognostic Score in Hodgkin's disease.
PG  - 1405-11
AB  - BACKGROUND: The International Prognostic Score (IPS) identifies seven independent 
      factors predicting progression-free and overall survival in advanced stage 
      Hodgkin's disease (HD). The IPS is also applicable in limited disease. However, 
      the IPS does not identify patients with a very poor prognosis. The aim of this 
      study was to define biological markers which may add to the IPS in predicting 
      outcome. PATIENTS AND METHODS: One hundred forty-five patients (> 15 years) with 
      HD of all stages and histopathology subgroups were included. In addition to 
      factors included in the IPS, serum levels of CRP, sCD4, sCD8, sCD25, sCD30, 
      sCD54, interleukin (IL)-10, beta2-microglobulin and thymidine kinase were 
      analysed. RESULTS: The strongest predictors of a poor cause-specific survival 
      (CSS) in univariate analyses were: increased serum levels of IL-10, sCD30 and 
      CRP, anaemia, low levels of albumin (P < 0.001); stage IV (P = 0.003), age > or = 
      45 years (P = 0.006), increased serum levels of sCD25 (P = 0.010), low lymphocyte 
      counts (P = 0.020). Serum IL-10 added prognostic information to that achieved by 
      the IPS: patients with a high score and increased serum IL-10 had a very poor 
      outcome with a five-year CSS of 38%. Patients with increased serum levels of 
      sCD30 and a high score also had a poor outcome with a five-year CSS of 54%. 
      CONCLUSION: Serum levels of IL-10 and sCD30 may add to IPS in prediction of 
      outcome in HD, and should be validated in large, prospective studies.
FAU - Axdorph, U
AU  - Axdorph U
AD  - Department of Medicine, Karolinska Hospital and Institutet, Stockholm, Sweden. 
      ulla.axdorph@ks.se
FAU - Sjoberg, J
AU  - Sjoberg J
FAU - Grimfors, G
AU  - Grimfors G
FAU - Landgren, O
AU  - Landgren O
FAU - Porwit-MacDonald, A
AU  - Porwit-MacDonald A
FAU - Bjorkholm, M
AU  - Bjorkholm M
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Blood Proteins)
RN  - 0 (Ki-1 Antigen)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (beta 2-Microglobulin)
RN  - 130068-27-8 (Interleukin-10)
RN  - EC 2.7.1.21 (Thymidine Kinase)
SB  - IM
MH  - Adult
MH  - Antigens, CD/blood
MH  - Biomarkers, Tumor/*blood
MH  - Blood Proteins/analysis
MH  - Cause of Death
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Hodgkin Disease/blood/*mortality/therapy
MH  - Humans
MH  - Interleukin-10/*blood
MH  - Ki-1 Antigen/*blood
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Proteins/*blood
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Prospective Studies
MH  - *Severity of Illness Index
MH  - Solubility
MH  - Survival Analysis
MH  - Thymidine Kinase/blood
MH  - Treatment Outcome
MH  - beta 2-Microglobulin/analysis
EDAT- 2001/01/06 11:00
MHDA- 2001/03/27 10:01
CRDT- 2001/01/06 11:00
PHST- 2001/01/06 11:00 [pubmed]
PHST- 2001/03/27 10:01 [medline]
PHST- 2001/01/06 11:00 [entrez]
AID - S0923-7534(19)55702-7 [pii]
AID - 10.1023/a:1026551727795 [doi]
PST - ppublish
SO  - Ann Oncol. 2000 Nov;11(11):1405-11. doi: 10.1023/a:1026551727795.